The Drugs Controller General of India (DCGI) has given approval to the CSIR and Laxai Life Sciences Private Limited to conduct clinical trial of Colchicine on COVID-19 patients, according to a statement on Saturday.
Ram Vishwakarma, the advisor to the CSIR Director General, said Colchicine in combination with standard care will be an important therapeutic intervention for COVID-19 patients with cardiac co-morbidities and also for reducing pro-inflammatory cytokines, leading to faster recovery.
A number of global studies have confirmed that cardiac complications during course of COVID-19 infections and post-Covid syndrome are leading to loss of many lives, and it is essential to look for new or repurposed drugs, he said.
"Council of Scientific & Industrial Research (CSIR), and Laxai Life Sciences Pvt Ltd Hyderabad, have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 patients, the statement said.
The partner CSIR institutes in this important clinical trial are the CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad and CSIR-Indian Institute of Integrative Medicine (IIIM), Jammu.
India is one of the largest producers of this key drug and if successful, it will be made available to patients at an affordable cost, IICT Director S Chandrasekhar said.
Laxai Life Sciences CEO Ram Upadhayay said the enrolment of patients has already begun at multiple sites across India and the trial is likely to be completed in the next 8-10 weeks.
He further added that this drug can be made available to a large population of India based on the results of this trial and regulatory approval.
Last week, the CSIR announced that it along with Laxai Life Sciences Pvt Ltd has initiated phase II clinical trials of anti-helminitic drug Niclosamide for treatment of COVID-19.
Niclosamide has been extensively used in the past for treatment of tapeworm infection in adults as well as children. The safety profile of this drug has been tested over time and has been found safe for human consumption at different dose levels, the CSIR said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU